• PARP7, STAT1/2, and EAE: Key Study Insights

  2026-10-06

  Xu et al. identify PARP7 as a suppressor of type I interferon signaling that promotes STAT1 and STAT2 modification, ubiquitination, and p62-associated autophagic degradation. Their mouse EAE findings connect this mechanism to reduced disease severity, while also underscoring the limits of translating an autoimmune disease model directly to multiple sclerosis therapy.

• TG003: Linking Clk2 to Splicing and Cancer

  2026-10-06

  TG003 is a Cdc2-like kinase inhibitor that connects kinase pharmacology with alternative splicing and cancer biology. This evidence-focused review examines what TG003 can reveal about Clk signaling, how the 2024 CLK2–BRCA1 study changes interpretation, and where translational boundaries remain.

• Doxycycline: Research Context and Evidence

  2026-10-05

  Doxycycline is a tetracycline antibiotic used in antimicrobial, host-response, metalloproteinase, gene-regulation, and cancer research. This overview separates established pharmacology from exploratory applications, compares evidence across cellular, animal, and clinical settings, and explains why antiproliferative findings should not be interpreted as proof of anticancer efficacy. It also distinguishes doxycycline from doxorubicin, the drug examined in the supplied nanocarrier study, and outlines important limitations involving exposure, tissue distribution, mitochondrial effects, microbiome changes, and model relevance.

• Cell Integrity and Ploidy Limits in Budding Yeast

  2026-10-05

  Barker, Murray, and Bell show that budding yeast can reach approximately 32–64C DNA content through repeated genome duplication, but that ploidy is constrained by cell-surface integrity rather than by chromosome content alone. The study connects increasing cell size and surface stress with an upper limit to polyploidy and identifies repression of ergosterol-biosynthesis genes as a molecular correlate, while leaving direct translational and antifungal implications open.

• Cy3 NHS Ester (Non-Sulfonated): Product Overview

  2026-10-04

  Cy3 NHS ester (non-sulfonated), SKU A8100, is a supplier-described orange fluorescent dye for conceptual amino-group labeling of proteins, peptides, and oligonucleotides. No matched paper evidence was provided, so performance claims remain unverified.

• Bile Acid Retention and Immune Escape in MASH-HCC

  2026-10-03

  A 2026 Cancer Letters study identifies a GPR120–FXR/ABCB11–bile acid–NLRC5 pathway that connects lipid-associated metabolic stress with defective MHC-I antigen presentation in MASH-HCC. Its genetic and pharmacological evidence suggests that reducing intracellular bile acid retention can improve tumor antigenicity and strengthen anti-PD-1 responses in mouse models, while clinical applicability remains un established.

• MOG (35-55) in EAE Research Workflows

  2026-10-02

  MOG (35-55) provides a sequence-defined trigger for experimental autoimmune encephalomyelitis, supporting controlled studies of neuroinflammation, demyelination, and immune-modulatory therapies. Its value increases when peptide handling, strain selection, and pathway-level assays are integrated into one reproducible workflow.

• PARP7 Inhibition Stabilizes STAT1/2 in EAE

  2026-10-01

  Xu et al. identify PARP7 as a suppressor of type I interferon signaling that ADP-ribosylates STAT1 and STAT2, promoting their ubiquitination and p62-dependent autophagic degradation. Inhibition of PARP7 restored interferon pathway activity and reduced experimental autoimmune encephalomyelitis in mice, linking a defined post-translational mechanism to disease-relevant neuroinflammation.

• Bifurcated Redox Sensing by TRPV1 and TRPA1

  2026-10-01

  The reference study shows that TRPV1 and TRPA1 distinguish singlet oxygen from hydrogen peroxide rather than responding to reactive oxygen species uniformly. By combining electrophysiology, calcium imaging, agonist-selective testing, and residue analysis, it identifies divergent channel responses with implications for mechanistic redox signaling studies.

• Bifurcated ROS Sensing by TRPV1 and TRPA1

  2026-09-30

  The reference study shows that TRPV1 and TRPA1 distinguish singlet oxygen from hydrogen peroxide through different channel-specific mechanisms. Its combination of electrophysiology, calcium imaging, agonist-selective testing, and residue analysis provides a framework for interpreting reactive oxygen species effects on ion-channel signaling.

• MK-8745: Selective Aurora A Inhibitor Workflows

  2026-09-30

  MK-8745 enables controlled studies of Aurora A–dependent mitotic arrest, tetraploidy, and apoptosis across cancer cell models. This workflow connects biochemical potency with practical experiments in p53 biology, non-Hodgkin lymphoma, retinoblastoma research, and tumor xenograft models while emphasizing formulation and interpretation controls.

• Rosiglitazone Workflow for PPARγ Metabolic Studies

  2026-09-29

  Build reproducible adipogenesis, insulin-response, and PPARG-variant rescue assays with Rosiglitazone, also known as Brl-49653. This guide connects practical dosing and controls with a recent FPLD3 study that used receptor activation to probe protein instability, mitochondrial dysfunction, and metabolic rescue.

• Carvacrol in Redox-Resolved Cell Assays

  2026-09-29

  Carvacrol is more than a TRPA1 agonist: it can help researchers separate reactive oxygen species sensing from downstream cell-fate responses. This guide translates recent channel biology into rigorous assay design for cell cycle research, apoptosis research, and mechanistic validation.

• KN-62: From CaMKII Mechanism to Translation

  2026-09-28

  KN-62 provides a focused pharmacological route to interrogate CaMKII-linked calcium signaling, secretion, metabolism, and cell-cycle phenotypes. This article connects that tool to emerging evidence that proteolytic signaling sustains social memory, while defining the controls translational researchers need before extending findings across biological domains.

• MOG (35-55): EAE Workflow and Assay Insights

  2026-09-28

  Use MOG (35-55) to establish a defined antigen challenge for experimental autoimmune encephalomyelitis (EAE) and investigate neuroinflammation in a multiple sclerosis research setting. This guide connects peptide handling and study design with recent evidence that PARP7 inhibition can alter type I interferon signaling and EAE outcomes.

8370 records 1/558 page Next 12345 下5页 Last page